## **Clinical Pharmacokinetics of Morphine**

Therapeutic Drug Monitoring 13, 1-23 DOI: 10.1097/00007691-199101000-00001

**Citation Report** 

#	Article	IF	CITATIONS
1	Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clinical Pharmacology and Therapeutics, 1991, 50, 294-298.	2.3	51
2	The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects British Journal of Clinical Pharmacology, 1992, 33, 617-621.	1.1	245
3	Effects of morphine on acquisition and maintenance of ethanol and water intake patterns in rats. Alcohol, 1992, 9, 433-440.	0.8	7
5	Determination of morphine-3-glucuronide in human urine by capillary zone electrophoresis and micellar electrokinetic capillary chromatography. Biomedical Applications, 1993, 616, 305-310.	1.7	49
6	Death from a morphine infusion during a sickle cell crisis. Journal of Pediatrics, 1993, 123, 322-325.	0.9	31
7	Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. Clinical Pharmacokinetics, 1993, 24, 413-420.	1.6	44
8	Immunoassay of alkaloids. Russian Chemical Reviews, 1993, 62, 787-798.	2.5	4
10	Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding ? a pilot study in 20 patients. Supportive Care in Cancer, 1994, 2, 123-127.	1.0	33
11	The use of chlorpromazine for symptom control in dying cancer patients. Journal of Pain and Symptom Management, 1994, 9, 341-345.	0.6	103
12	Differential hemodynamic, metabolic and hormonal effects of morphine and morphine-6-glucuronide. Brain Research, 1994, 664, 126-132.	1.1	30
13	Pain control: some aspects of day-to-day management. European Journal of Cancer Care, 1994, 3, 79-86.	0.7	4
14	Lacrimal and Plasmatic Kinetics of Morphine After an Ophthalmic Delivery of Three Different Formulations. Drug Development and Industrial Pharmacy, 1994, 20, 1147-1158.	0.9	6
15	Induction of micronuclei in murine lymphocytes by morphine. Environmental and Molecular Mutagenesis, 1995, 25, 279-283.	0.9	18
17	Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain Journal of Clinical Oncology, 1995, 13, 1004-1008.	0.8	73
18	Advantages and Disadvantages of Combining Sedative Agents. Critical Care Clinics, 1995, 11, 903-912.	1.0	20
19	Physiological Aspects of Aging. Drugs and Aging, 1995, 7, 212-225.	1.3	29
20	Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. Journal of Pediatrics, 1995, 126, 461-467.	0.9	65
21	Laboratory diagnosis of poisonings. , 1996, , 25-236.		5

#	Article	IF	CITATIONS
22	Management of chronic pain. Part I. Disease-a-Month, 1996, 42, 385-454.	0.4	17
23	Pharmacokinetics of Opioids in Renal Dysfunction. Clinical Pharmacokinetics, 1996, 31, 410-422.	1.6	156
24	Pain and Symptom Management in Palliative Care. Cancer Control, 1996, 3, 204-213.	0.7	24
25	Morphine for Postoperative Analgesia. A Comparison of Intramuscular and Subcutaneous Routes of Administration. Anaesthesia and Intensive Care, 1996, 24, 574-578.	0.2	22
26	In vitro and in vivo evaluation of polylactide and polylactide-co-glycolide microspheres of morphine for site-specific delivery. International Journal of Pharmaceutics, 1996, 134, 37-46.	2.6	15
27	Effects of Oral Morphine on Cold Pressor Tolerance Time and Neuropsychological Performance. Neuropsychopharmacology, 1996, 15, 252-262.	2.8	50
28	Orales Papaverin reduziert die morphinbedingte Obstipation ohne Abschw�chung der Analgesie nach oralem Morphin. Schmerz, 1996, 10, 27-35.	2.7	51
29	Depression by morphine-6-glucuronide of nociceptive activity in rat thalamus neurons: comparison with morphine. Brain Research, 1996, 722, 132-138.	1.1	12
30	Postmortem distribution pattern of morphine and morphine glucuronides in heroin overdose. International Journal of Legal Medicine, 1996, 109, 118-124.	1.2	44
31	Rectal administration of morphine in children. Acta Anaesthesiologica Scandinavica, 1996, 40, 445-451.	0.7	19
32	The Influence of Preanalytical Factors on Concentrations of Morphine and Metabolites in Patients Receiving Morphine. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 82-85.	0.0	8
33	The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans and Animals, and the Importance of the Metabolites to the Pharmacological Effects of Morphine. Drug Metabolism Reviews, 1996, 28, 345-472.	1.5	190
34	A Pharmacodynamic Study of Morphine and Its Glucuronide Metabolites After Single Morphine Dosing in Cancer Patients with Pain. Cancer Investigation, 1997, 15, 542-547.	0.6	18
35	Plasma Concentrations of Heroin and Morphine-Related Metabolites after Intranasal and Intramuscular Administration. Journal of Analytical Toxicology, 1997, 21, 105-111.	1.7	52
36	Lack of Analgesic Activity of Morphine-6-glucuronide after Short-term Intravenous Administration in Healthy VolunteersÂ. Anesthesiology, 1997, 87, 1348-1358.	1.3	107
37	Emerging Neuropsychiatric Toxicities of Opioids. Journal of Pain and Palliative Care Pharmacotherapy, 1997, 5, 3-29.	0.2	17
38	The Pharmacokinetic Profiles of Two Variations of a Sustained Release Morphine Sulfate Formulation Intended for Once-Daily Administration. Clinical Drug Investigation, 1997, 14, 53-58.	1.1	0
39	Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users. Clinical Pharmacokinetics, 1997, 33, 344-400.	1.6	83

		CITATION REPORT		
#	Article		IF	Citations
40	Loss of analgesic effect of morphine due to coadministration of rifampin. Pain, 1997, 7	′2, 261-267.	2.0	90
41	Concentration-Effect Relationship after Intravenous Hydromorphone Administration: L Effect Compartment Model and System Analysis to Minimize Hysteresis of Effects. Pai Management, 1997, 2, 167-172.	lse of An n Research and	0.7	0
42	EFFECTS OF ALBUMIN ON THE DISPOSITION OF MORPHINE AND MORPHINE-3-GLUCU ISOLATED PERFUSED LIVER. Clinical and Experimental Pharmacology and Physiology, 1		0.9	2
43	Recommended use of morphine in neonates, infants and children based on a literature 1—Pharmacokinetics. Paediatric Anaesthesia, 1997, 7, 5-11.	review: Part	0.6	183
44	Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine A co two injection sites. Acta Anaesthesiologica Scandinavica, 1998, 42, 323-328.	omparison of	0.7	9
45	Controlled-release oxycodone compared with controlled-release morphine in the treat cancer pain: A randomized, double-blind, parallel-group study. European Journal of Pair 239-249.		1.4	158
46	Peak Plasma Concentrations After Oral Morphine. Journal of Pain and Symptom Manag 388-402.	şement, 1998, 16,	0.6	108
47	Variability of morphine disposition during long-term subcutaneous infusion in terminal patients. European Journal of Clinical Pharmacology, 1998, 53, 325-330.	ly ill cancer	0.8	22
48	Systematic review of factors affecting the ratios of morphine and its major metabolite 43-53.	s. Pain, 1998, 74,	2.0	140
49	Genetic toxicology of abused drugs: a brief review. Mutagenesis, 1998, 13, 557-565.		1.0	66
50	Lesson of the week: Morphine induced allodynia in a child with brain tumour  What is British Medical Journal, 1999, 319, 627-629.	allodynia?. BMJ:	2.4	45
51	Prolonged Opioid Antagonism with Naloxone in Chronic Renal Failure. Pharmacotheraj 897-901.	by, 1999, 19,	1.2	11
52	Modern concepts of paediatric analgesia. , 1999, 83, 1-20.			27
53	Morphine-Induced Ventilatory Failure After Spinal Cord Compression. Journal of Pain a Management, 1999, 18, 140-142.	nd Symptom	0.6	13
54	Transfer of morphine across the human placenta and its interaction with naloxone. Life 1999, 65, 2359-2371.	? Sciences,	2.0	40
55	Pharmacokinetics of Opioids in Liver Disease. Clinical Pharmacokinetics, 1999, 37, 17-	40.	1.6	259
56	Fetal response to maternally administered morphine. American Journal of Obstetrics at 2000, 183, 424-430.	nd Gynecology,	0.7	50
57	Start of oral morphine to cancer patients: effective serum morphine concentrations ar contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eu of Clinical Pharmacology, 2000, 55, 713-719.		0.8	87

#	Article	IF	CITATIONS
58	Morphine-6-Clucuronide. Clinical Pharmacokinetics, 2001, 40, 485-499.	1.6	108
59	Endogenous opioids, placebo response, and pain. Lancet, The, 2001, 357, 1901-1902.	6.3	22
60	Crohn's disease: genetic susceptibility, bacteria, and innate immunity. Lancet, The, 2001, 357, 1902-1904.	6.3	66
61	Pharmacology of opioid analgesia: clinical principles. , 2001, , 195-229.		5
62	Contemporary Drug Therapy in Palliative Care: New Directions. Cancer Investigation, 2001, 19, 413-423.	0.6	9
63	Diskurs zu Morphinbefunden im Autopsieblut nach palliativer Schmerzbehandlung. Rechtsmedizin, 2001, 11, 205-211.	2.6	0
64	Hydromorphone: pharmacology and clinical applications in cancer patients. Supportive Care in Cancer, 2001, 9, 84-96.	1.0	146
65	Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors. Journal of Pharmaceutical Sciences, 2001, 90, 749-784.	1.6	436
66	Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer, 2001, 84, 587-593.	2.9	759
67	Methadone-induced myoclonus in advanced cancer. American Journal of Hospice and Palliative Medicine, 2001, 18, 51-53.	0.8	31
68	The efficacy and side effects of continuous infusion intravenous morphine (CIVM) for pain and symptoms due to advanced cancer. American Journal of Hospice and Palliative Medicine, 2002, 19, 343-350.	0.8	10
69	Prediction of Volume of Distribution Values in Humans for Neutral and Basic Drugs Using Physicochemical Measurements and Plasma Protein Binding Data. Journal of Medicinal Chemistry, 2002, 45, 2867-2876.	2.9	194
70	Clinical Pharmacokinetics of Morphine. Journal of Pain and Palliative Care Pharmacotherapy, 2002, 16, 5-18.	0.5	93
71	Contribution of Morphine-6-Glucuronide to Antinociception following Intravenous Administration of Morphine to Healthy Volunteers. Journal of Clinical Pharmacology, 2002, 42, 569-576.	1.0	71
72	Protein binding predictions in infants. AAPS PharmSci, 2002, 4, 19-26.	1.3	153
73	The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel. European Journal of Pharmacology, 2002, 440, 7-16.	1.7	44
76	Morphine in cancer pain management: a practical guide. Supportive Care in Cancer, 2002, 10, 13-35.	1.0	84
77	Endogenous morphine modulates acute thermonociception in mice. Journal of Neurochemistry, 2002, 80, 271-277	2.1	19

#	Article	IF	Citations
78	Long-term rectal administration of high-dose sustained-release morphine tablets. Supportive Care in Cancer, 2002, 10, 653-655.	1.0	11
79	A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine. Clinical Pharmacology and Therapeutics, 2003, 73, 566-574.	2.3	149
80	Bioavailability of a morphine suppository is increased after intracolostomal administration in colostoma-constructed rabbits. International Journal of Pharmaceutics, 2003, 265, 65-73.	2.6	1
81	Pharmacokinetic Interactions with Rifampicin. Clinical Pharmacokinetics, 2003, 42, 819-850.	1.6	591
82	A syllabus for fellowship education in palliative medicine. American Journal of Hospice and Palliative Medicine, 2003, 20, 279-289.	0.8	9
83	Analgesic Efficacy of Inhaled Morphine in Patients after Bunionectomy Surgery. Anesthesiology, 2003, 99, 693-700.	1.3	60
84	Critical Care Neurology and Neurosurgery. , 2004, , .		23
85	GLUCURONIDATION OF THE OXIDATIVE CYTOCHROME P450-MEDIATED PHENOLIC METABOLITES OF THE ENDOCRINE DISRUPTOR PESTICIDE: METHOXYCHLOR BY HUMAN HEPATIC UDP-GLUCURONOSYL TRANSFERASES. Drug Metabolism and Disposition, 2004, 32, 742-751.	1.7	15
86	Opioid Partial Agonist Effects of 3-O-Methylnaltrexone in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1030-1039.	1.3	6
87	METABOLISM OF OPIOIDS IS ALTERED IN LIVER MICROSOMES OF SICKLE CELL TRANSGENIC MICE. Drug Metabolism and Disposition, 2004, 32, 98-104.	1.7	28
88	Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study. BMC Clinical Pharmacology, 2004, 4, 7.	2.5	11
89	Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sciences, 2004, 74, 2143-2155.	2.0	180
91	Genetic variability and clinical efficacy of morphine. Acta Anaesthesiologica Scandinavica, 2005, 49, 902-908.	0.7	94
92	Contribution to variability in response to opioids. Supportive Care in Cancer, 2005, 13, 145-152.	1.0	44
93	Differential effects of two analgesic drugs, morphine chlorhydrate and acetylsalicylic acid, on thalamic mast cell numbers in rat. Journal of Neuroimmunology, 2005, 169, 106-115.	1.1	6
94	Immunomodulatory effect of morphine: therapeutic implications. Expert Opinion on Drug Safety, 2005, 4, 669-675.	1.0	26
95	Effects of opioid antagonists and morphine in a hippocampal hypoxia/hypoglycemia model. Neuropharmacology, 2005, 49, 1160-1169.	2.0	43
96	Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain, 2006, 123, 294-305.	2.0	69

#	Article	IF	CITATIONS
97	Comparison between effectiveness of intravenous patient-controlled analgesia and epidural analgesia in patients undergoing Cesarean section. The Pain Clinic, 2006, 18, 31-35.	0.1	0
98	Effects of extradural morphine on end-tidal isoflurane concentration and physiological variables in pigs undergoing abdominal surgery: a clinical study. Veterinary Anaesthesia and Analgesia, 2006, 33, 307-312.	0.3	7
99	Environmental and genetic factors associated with morphine response in the postoperative period. Clinical Pharmacology and Therapeutics, 2006, 79, 316-324.	2.3	216
100	QSPR models for the prediction of apparent volume of distribution. International Journal of Pharmaceutics, 2006, 319, 82-97.	2.6	57
101	Morphine Withdrawal Dramatically Reduces Lymphocytes in Morphine-Dependent Macaques. Journal of NeuroImmune Pharmacology, 2006, 1, 250-259.	2.1	21
102	The Influence of Collection Site and Methods on Postmortem Morphine Concentrations in a Porcine Model. Journal of Analytical Toxicology, 2006, 30, 651-658.	1.7	28
103	The Pharmacologic Management of Cancer Pain. Journal of Palliative Medicine, 2007, 10, 1369-1394.	0.6	41
104	Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC <sub>50,u</sub> and Correlation of in Vitro, Preclinical, and Clinical Data. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 346-355.	1.3	145
105	Morphine and Heroin Differentially Modulate In Vivo Hippocampal LTP in Opiate-Dependent Rat. Neuropsychopharmacology, 2007, 32, 1738-1749.	2.8	72
106	The Prevalence and Management of Chronic Pain in End-Stage Renal Disease. Journal of Palliative Medicine, 2007, 10, 1277-1287.	0.6	76
107	Negative Relationship Between Morphine Analgesia and P-Glycoprotein Expression Levels in the Brain. Journal of Pharmacological Sciences, 2007, 105, 353-360.	1.1	79
108	Morphine Metabolism After Major Liver Surgery. Anesthesia and Analgesia, 2007, 104, 1409-1414.	1.1	40
109	Opioid-related narcosis in a woman with myopathy receiving magnesium. International Journal of Obstetric Anesthesia, 2007, 16, 367-369.	0.2	6
110	Critical care sedation for neuroscience patients. Journal of the Neurological Sciences, 2007, 261, 16-34.	0.3	27
111	Opioid Analgesics. , 2007, , 939-964.		8
112	Opioides. , 2007, , 455-470.		0
113	Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 93-107.	1.5	82
114	Cationâ€selective exhaustive injection and sweeping micellar electrokinetic chromatography for analysis of morphine and its four metabolites in human urine. Electrophoresis, 2008, 29, 2340-2347.	1.3	26

#	Article	IF	CITATIONS
115	The delivery and antinociceptive effects of morphine and its ester prodrugs from lipid emulsions. International Journal of Pharmaceutics, 2008, 353, 95-104.	2.6	26
116	Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief. Clinical Pharmacology and Therapeutics, 2008, 83, 559-566.	2.3	303
117	Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine,) Tj ETQq0 0 0	rgBP/Over	lock $10$ Tf 50
118	The effects of different analgesic regimens on transcutaneous CO <sub>2</sub> after major surgery. Anaesthesia, 2008, 63, 814-821.	1.8	18
119	Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. British Journal of Clinical Pharmacology, 2008, 66, 781-791.	1.1	20
120	Morphine Bioavailability from a Topical Gel Formulation in Volunteers. Journal of Pain and Symptom Management, 2008, 35, 314-320.	0.6	28
121	Titration morphinique intraveineuse aux urgences. JEUR/Journal Européen Des Urgences, 2008, 21, 45-55.	0.0	0
122	Opioid Rotation from Oral Morphine to Oral Oxycodone in Cancer Patients with Intolerable Adverse Effects: An Open-Label Trial. Japanese Journal of Clinical Oncology, 2008, 38, 296-304.	0.6	55
123	Clinical pharmacology of analgesics in old age and frailty. Reviews in Clinical Gerontology, 2009, 19, 103-118.	0.5	14
124	Increased Locomotor Activity Induced by Heroin in Mice: Pharmacokinetic Demonstration of Heroin Acting as a Prodrug for the Mediator 6-Monoacetylmorphine in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 153-161.	1.3	76
125	Neonatal Stress or Morphine Treatment Alters Adult Mouse Conditioned Place Preference. Neonatology, 2009, 95, 230-239.	0.9	62
126	Vaccines against morphine/heroine and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin, 2009, 5, 214-229.	2.4	48
127	Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. European Journal of Cancer Care, 2009, 18, 331-337.	0.7	36
128	Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study. Clinical Pharmacology and Therapeutics, 2009, 86, 634-643.	2.3	122
129	Opioids for the Treatment of Chronic Non-Cancer Pain in Older People. Drugs and Aging, 2009, 26, 63-73.	1.3	30
130	A survey of post-craniotomy analgesia in British neurosurgical centres: time for perceptions and prescribing to change?. British Journal of Neurosurgery, 2009, 23, 538-542.	0.4	33
131	Quantitative structure-pharmacokinetic relationship modelling: apparent volume of distribution. Journal of Pharmacy and Pharmacology, 2010, 56, 339-350.	1.2	28
132	Pharmacokinetics of morphine after intravenous administration in broiler chickens. Journal of Veterinary Pharmacology and Therapeutics, 2010, 33, 515-518.	0.6	15

щ		IF	CITATIONS
#	ARTICLE Pharmacokinetics of intra-articular morphine in horses with lipopolysaccharide-induced synovitis.	IF	CITATIONS
133	Veterinary Anaesthesia and Analgesia, 2010, 37, 186-195.	0.3	20
134	The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain. Palliative Medicine, 2010, 24, 9-16.	1.3	19
135	Developmental neurotoxicity of abused drugs. , 2011, , 341-353.		1
136	The Disposition of Morphine and Morphine-3-glucuronide in the Isolated Perfused Rat Liver: Effects of Altered Perfusate Flow Rate. Journal of Pharmacy and Pharmacology, 2011, 48, 498-504.	1.2	7
137	Can Non-steroidal Anti-inflammatory Drugs Act as Metalloproteinase Modulators? An In-vitro Study-of Inhibition of Collagenase Activity. Journal of Pharmacy and Pharmacology, 2011, 50, 1417-1423.	1.2	21
138	Increased Clearance of Morphine in Sickle Cell Disease: Implications for Pain Management. Journal of Pain, 2011, 12, 531-538.	0.7	41
139	Oral-Parenteral Conversion Factor for Morphine in Palliative Cancer Care: A Prospective Randomized Crossover Pilot Study. Pain Research and Treatment, 2011, 2011, 1-5.	1.7	5
140	Dose Conversion in Opioid Rotation from Continuous Intravenous Infusion of Morphine Hydrochloride Injection to Fentanyl Patch in the Management of Cancer Pain. Yakugaku Zasshi, 2011, 131, 463-467.	0.0	9
141	Distinct pharmacological properties of morphine metabolites at Gi-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor. Biochemical Pharmacology, 2011, 81, 1248-1254.	2.0	48
142	A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography–tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 400, 715-728.	1.9	70
143	Concentration ratios of free-morphine to free-codeine in femoral blood in heroin-related poisoning deaths. Legal Medicine, 2011, 13, 171-173.	0.6	43
144	Intra-articular injection of morphine to the horse: establishment of an <i>in vitro–in vivo</i> relationship Drug Development and Industrial Pharmacy, 2011, 37, 1043-1048.	0.9	5
145	Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: Case report and a review of the literature. Human and Experimental Toxicology, 2011, 30, 1399-1403.	1.1	14
146	Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions. American Journal of Drug and Alcohol Abuse, 2011, 37, 205-217.	1.1	137
147	Effects of Anesthetics, Sedatives, and Opioids on Ventilatory Control. , 2012, 2, 2281-2367.		15
148	First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 195-203.	0.8	54
149	Concentrations of free-morphine in peripheral blood after recent use of heroin in overdose deaths and in apprehended drivers. Forensic Science International, 2012, 215, 18-24.	1.3	31
150	Synthesis and bioanalytical evaluation of morphineâ€3â€Oâ€sulfate and morphineâ€6â€Oâ€sulfate in human uri and plasma using LCâ€MS/MS. Journal of Separation Science, 2012, 35, 367-375.	ne 1.3	5

#	ARTICLE	IF	CITATIONS
151	Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): <i>in silico</i> and <i>in vitro</i> insights. Drug Metabolism Reviews, 2013, 45, 231-252.	1.5	17
152	Pain, Agitation, Delirium, and Neuromuscular Blockade. Critical Care Nursing Quarterly, 2013, 36, 356-369.	0.4	8
153	Dual effect of morphine in longâ€ŧerm social memory in rat. British Journal of Pharmacology, 2013, 168, 1786-1793.	2.7	10
154	Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?. Journal of Pain Research, 2013, 6, 331.	0.8	79
155	The effect of plasticizers on the erosion and mechanical properties of polymeric films. Journal of Biomaterials Applications, 2014, 28, 779-789.	1.2	14
156	A Monoclonal Antibody Specific for 6-Monoacetylmorphine Reduces Acute Heroin Effects in Mice. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 568-576.	1.3	26
157	Morphine overdose in a patient on haemodialysis with stage 5 chronic kidney disease. Journal of Renal Nursing, 2014, 6, 181-184.	0.1	0
158	Pharmacological Management of Cancer-Related Pain. Cancer Control, 2015, 22, 412-425.	0.7	43
159	Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans. Journal of Addiction Medicine, 2015, 9, 204-210.	1.4	94
160	Oral Sedation Postdischarge Adverse Events in Pediatric Dental Patients. Anesthesia Progress, 2015, 62, 91-99.	0.2	19
161	Morphine versus Hydromorphone: Does Choice of Opioid Influence Outcomes?. Pain Research and Treatment, 2015, 2015, 1-6.	1.7	12
162	Predicted Structures for Kappa Opioid G-Protein Coupled Receptor Bound to Selective Agonists. Journal of Chemical Information and Modeling, 2015, 55, 614-627.	2.5	16
163	Variable Patterns of Continuous Morphine Infusions at End of Life. Journal of Palliative Medicine, 2015, 18, 786-789.	0.6	12
164	Physical Dependence and Plasma Concentrations of Morphine in Rats. Journal of Drug Abuse, 2016, 2, .	0.2	0
165	A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management. Journal of Clinical Pharmacology, 2016, 56, 785-793.	1.0	4
166	Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 669-680.	1.5	41
167	Perioperative pain management for hip fracture patients. Orthopaedics and Trauma, 2016, 30, 145-152.	0.2	11
168	Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clinical Pharmacokinetics, 2016, 55, 1573-1589.	1.6	80

#	Article	IF	CITATIONS
169	Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally III Adult Patients. Clinical Pharmacokinetics, 2016, 55, 697-709.	1.6	23
170	Simultaneous detection of morphine and codeine in urine samples of heroin addicts using multi-walled carbon nanotubes modified SnO2–Zn2SnO4 nanocomposites paste electrode. Applied Surface Science, 2016, 363, 490-498.	3.1	30
171	A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Clinical Pharmacokinetics, 2017, 56, 733-746.	1.6	13
172	Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metabolism Reviews, 2017, 49, 105-138.	1.5	82
173	Sebacoyl Dinalbuphine Ester Extended-release Injection for Long-acting Analgesia. Clinical Journal of Pain, 2017, 33, 429-434.	0.8	18
174	Racemic Salsolinol and its Enantiomers Act as Agonists of the μ-Opioid Receptor by Activating the Gi Protein-Adenylate Cyclase Pathway. Frontiers in Behavioral Neuroscience, 2017, 10, 253.	1.0	20
175	Developmental Neurotoxicity of Abused Drugs. , 2017, , 413-429.		0
176	Quantitative Structure – Pharmacokinetic Relationships for Plasma Clearance of Basic Drugs with Consideration of the Major Elimination Pathway. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 135.	0.9	8
177	Pregabalin Reduces Acute Inflammatory and Persistent Pain Associated with Nerve Injury and Cancer in Rat Models of Orofacial Pain. Journal of Oral and Facial Pain and Headache, 2018, 28, 350-359.	0.7	18
178	Influence of OPRM1 Polymorphism on Postoperative Pain After Intrathecal Morphine Administration in Italian Patients Undergoing Elective Cesarean Section. Clinical Journal of Pain, 2018, 34, 178-181.	0.8	10
179	The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine. International Journal of Legal Medicine, 2018, 132, 415-424.	1.2	7
180	The Effect of Epidural Morphine-Bupivacaine Combined with a Low Dose of Naloxone on Respiratory Function and Analgesia in Patients with Chronic Low-Back Pain. Journal of Health & Medical Informatics, 2018, 09, .	0.2	0
181	Genetic Engineering Potential of Hairy Roots of Poppy (Papaver spp.) for Production of Secondary Metabolites, Phytochemistry, and In Silico Approaches. , 2018, , 569-597.		0
182	Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. Journal of Medicinal Chemistry, 2018, 61, 10345-10374.	2.9	67
183	Trends in Prehospital Analgesia Administration by US Forces From 2007 Through 2016. Prehospital Emergency Care, 2019, 23, 271-276.	1.0	25
184	Predicting and Understanding the Human Microbiome's Impact on Pharmacology. Trends in Pharmacological Sciences, 2019, 40, 495-505.	4.0	38
185	Treatment of Hypertensive Cardiogenic Edema with Intravenous High-Dose Nitroglycerin in a Patient Presenting with Signs of Respiratory Failure: A Case Report and Review of the Literature. American Journal of Case Reports, 2019, 20, 83-90.	0.3	7
187	Pain-related behavior and brain activation in cynomolgus macaques with naturally occurring endometriosis. Human Reproduction, 2019, 34, 469-478.	0.4	9

ARTICLE IF CITATIONS # Clinical Pharmacokinetics., 2019,, 409-424. 188 8 Antenatal and Postnatal Analgesia. BJOC: an International Journal of Obstetrics and Gynaecology, 189 1.1 28 2019, 126, e114-e124. Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory 190 0.8 18 drugs and opioids. Personalized Medicine, 2019, 16, 171-184. Morphineâ€6â€Glucuronide Isomersâ€Synthesis and Biological Evaluation. Bulletin of the Korean Chemical Society, 2020, 41, 1073-1079. Pain Management in Plastic Surgery. Clinics in Plastic Surgery, 2020, 47, 191-201. 192 0.7 18 Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units. Expert Opinion on Drug Metabolism and Toxicology, 2021, 1.5 17, 273-289 194 Palliative Care and Cancer Pain., 2021, , 91-111. 1 Breastfeeding and drugs. The Obstetrician and Gynaecologist, 2021, 23, 94-102. 0.2 Effectiveness and safety of repetitive transcranial magnetic stimulation for the treatment of 196 0.4 3 morphine dependence. Medicine (United States), 2021, 100, e25208. Klinisch-pharmakologische Grundlagen der Schmerztherapie., 2005, , 69-120. Klinisch-pharmakologische Grundlagen der Schmerztherapie., 2009, , 75-130. 198 3 199 Handling of Drugs in Children with Abnormal Renal Function-., 2015, , 1-28. Rückenmarknahe Applikation von analgetisch wirkenden Substanzen., 2001, , 80-105. 200 1 Opioids: clinical use., 2006, , 443-457. 24 Clinical Toxicology., 2012, , 1109-1188. 202 2 Side effects of morphine administration in cancer patients. Cancer Nursing, 1998, 21, 289-297. Acute Trauma Alters Morphine Clearance. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 204 1.1 20 39, 749-752. Effect of Drugs and Cocaine Metabolites on Cocaine and Cocaethylene Binding to Human Serum In Vitro. Therapeutic Drug Monitoring, 1997, 19, 427-430.

#	Article	IF	Citations
206	Pain therapy in multiple myeloma — clinical experience from an observational study. The Pain Clinic, 2006, 18, 131-136.	0.1	3
207	Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliative Medicine, 2003, 17, 679-687.	1.3	52
209	Management of acute and post-operative pain in chronic kidney disease. F1000Research, 0, 2, 28.	0.8	8
210	Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain. Current Neuropharmacology, 2017, 15, 1156-1173.	1.4	83
212	Narkotische Analgetika (Opiate und Opioide). , 2001, , 33-45.		0
213	Klinisch-pharmakologische Grundlagen der Schmerztherapie insbesondere des Neugeborenenalters. , 2001, , 47-99.		0
214	ãf¢ãf«ãf'ãfã®è,管ã«ãŠã'ã,<代謕癌æ,£è€ã§ã®ææè°Ž. Japanese Journal of Clinical Pharmacology and Tl	he <b>cap</b> eutic	s,@002, 33,
215	Interindividual Variation of Ratio of Concentration of Plasma Morphine and Its Metabolites in Cancer Patients Japanese Journal of Clinical Pharmacology and Therapeutics, 2002, 33, 255-261.	0.1	0
216	Klinisch-pharmakologische Grundlagen der Schmerztherapie. , 2003, , 81-144.		0
217	Sedation and Analgesia in the Critically III Neurology and Neurosurgery Patient. , 2004, , 221-245.		1
218	Rückenmarknahe Verfahren. , 2004, , 109-128.		0
219	The Perioperative Management of the Acute Care Surgical Patient. , 2007. , 67-83.		1

222	Manejo farmacológico del dolor en el paciente oncológico. Acta Medica Costarricense, 2008, 46, .	0.1	1
224	Dose Conversion during Opioid Rotation from Continuous Intravenous Infusion of Morphine Hydrochloride to Oral Administration of Oxycodone Sustained-release Tablets. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2012, 38, 170-176.	0.0	1

225Pharmacokinetic data on analgesic and antimigraine agents. , 1992, , 4-6.0226Pharmacology of Opioid Analgesic Agents — A Contemporary View. , 1993, , 14-30.0

227 Opioidagonisten: Spezielle Pharmakologie. , 1994, , 220-240.

**CITATION REPORT** 

	CITATION R	CITATION REPORT		
#	Article	IF	CITATIONS	
230	Handling of Drugs in Children with Abnormal Renal Function. , 2016, , 2267-2293.		0	
231	Emerging trends in point-of-care sensors for illicit drugs analysis. Talanta, 2022, 238, 123048.	2.9	25	
232	The Management of Pain in Spinal Malignancies. , 2006, , 349-359.		0	
234	Developmental neurotoxicity of drugs of abuse. , 2022, , 359-377.		Ο	
235	Diamorphine pharmacokinetics and conversion factor estimates for intranasal diamorphine in paediatric breakthrough pain:systematic review. BMJ Supportive and Palliative Care, 2023, 13, e485-e493.	0.8	1	
236	Pharmacokinetic modeling and simulation to understand diamorphine doseâ€response in neonates, children, and adolescents. Paediatric Anaesthesia, 2022, 32, 716-726.	0.6	4	
237	Opioids in the Elderly Patients with Cognitive Impairment: A Narrative Review. Pain and Therapy, 2022, 11, 381-394.	1.5	7	
238	Ascorbic acid inhibits the acquisition and expression of morphine-induced conditioned place preference and sensitization in male Swiss-Webster mice. Physiology and Pharmacology, 2021, .	0.1	0	
240	Management of acute and post-operative pain in chronic kidney disease. F1000Research, 2013, 2, 28.	0.8	5	
241	The Anesthesiologist Contribution to Management of Acute Pancreatitis. , 0, , .		0	
242	PHARMACOLOGIC MANAGEMENT OF CANCER PAIN. Nursing Clinics of North America, 1995, 30, 745-763.	0.7	5	
243	In Silico Modeling for Ex Vivo Placental Transfer of Morphine. Journal of Clinical Pharmacology, 2022, 62, 140-146.	1.0	2	
244	Metabolic Profiling and Investigation of the Modulatory Effect of Fagonia cretica L. Aerial Parts on Hepatic CYP3A4 and UGT2B7 Enzymes in Streptozotocin—Induced Diabetic Model. Antioxidants, 2023, 12, 119.	2.2	1	
245	Changes in Plasma Metabolic Signature upon Acute and Chronic Morphine Administration in Morphine-Tolerant Mice. Metabolites, 2023, 13, 434.	1.3	0	
246	Heroin and its metabolites: relevance to heroin use disorder. Translational Psychiatry, 2023, 13, .	2.4	10	